Cisplatin is an effective chemotherapy drug that induces peripheral neuropathy in cancer patients. In rodent dorsal root ganglion neurons, cisplatin binds nuclear and mitochondrial DNA (mtDNA) inducing DNA damage and apoptosis. Platinum-mtDNA adducts inhibit mtDNA replication and transcription leading to mitochondrial degradation. Cisplatin also induces climbing deficiencies associated with neuronal apoptosis in adult Drosophila melanogaster. Here we used Drosophila larvae that express green fluorescent protein in the mitochondria of motor neurons to observe the effects of cisplatin on mitochondrial dynamics and function. Larvae treated with 10 μg/ml cisplatin had normal survival with deficiencies in righting and heat sensing behavior. Behavior was abrogated by, the pan caspase inhibitor, p35. However, active caspase 3 was not detected by immunostaining. There was a 27% decrease in mitochondrial membrane potential and a 42% increase in reactive oxygen species (ROS) in mitochondria along the axon. Examination of mitochondrial axonal trafficking showed no changes in velocity, flux or mitochondrial length. However, cisplatin treatment resulted in a greater number of stationary organelles caused by extended pausing during axonal motility. These results demonstrate that cisplatin induces behavior deficiencies in Drosophila larvae, decreased mitochondrial activity, increased ROS production and mitochondrial pausing without killing the larvae. Thus, we identified particular aspects of mitochondrial dynamics and function that are affected in cisplatin-induced peripheral neuropathy and may represent key therapeutic targets.
Introduction
Cisplatin-induced peripheral neuropathy is a dose-limiting side effect occurring in 30-40% of cancer patients (Johnson et al., 2015; Windebank and Grisold, 2008) . Symptoms are mainly sensory including tingling, numbness, paresthesia and pain (Cavaletti and Marmiroli, 2010; O'Reilly et al., 2014) . Some patients experience a worsening of the sensory symptoms for 2-6 months after completion of their treatment, which is a phenomenon known as "coasting" (Miltenburg and Boogerd, 2014; Reinstein et al., 1980) . Long-term neuropathy lowers quality of life for many cancer survivors and currently there are no preventive therapies for cisplatin-induced peripheral neuropathy. Chronic neurotoxicity is also caused by the other commonly used platinum compounds, carboplatin and oxaliplatin. Understanding the underlying mechanisms of chemotherapy-induced peripheral neuropathy (CIPN) is critical for the development of effective therapeutic approaches (Albers et al., 2011) .
Cisplatin neurotoxicity is attributed to the formation of platinum-DNA (Pt-DNA) adducts leading to cellular stress and apoptosis (Eastman, 1987; McDonald et al., 2005) . Cisplatin binds both nuclear DNA (nDNA) and mitochondrial DNA (mtDNA) inducing DNA damage and apoptosis in rat dorsal root ganglion (DRG) neurons, in vitro (McDonald et al., 2005; McDonald and Windebank, 2002; Podratz et al., 2011a; Ta et al., 2006; Ta et al., 2009) . Cisplatin binds nDNA leading to upregulation of p53, cell cycle re-entry and translocation of BCL2-associated X (bax) protein to the mitochondria (Fischer et al., 2001; Gill and Windebank, 1998; McDonald and Windebank, 2002) . Cisplatin also binds mtDNA inhibiting replication and transcription leading to mitochondrial degradation (Podratz et al., 2011a) . Accumulation of Pt-DNA adducts is higher in DRG neurons although the rate of repair is similar to other cell types (McDonald et al., 2005) . Pt-DNA adducts are removed by nucleotide excision repair in the nucleus. However, this mechanism does not exist in mitochondria (Croteau et al., 1999; Larsen et al., 2005) . Pt-mtDNA adducts may play an important role in the mechanism of cisplatin-induced neurotoxicity. 
